Navigation Links
Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
Date:1/24/2008

Company Received $5.2 Million in Cost Recovery from EAP in 2007

RICHMOND, Va., Jan. 24 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, today provided an update on the IPLEX(TM) Expanded Access Program (EAP) in Italy for the treatment of Amyotrophic Lateral Sclerosis (ALS). Since early 2007, the EAP has grown to include 15 physicians and approximately 70 subjects have been enrolled into the program. Additional subjects continue to be enrolled into the program. IPLEX(TM) appears to have been safe and well tolerated in the subject population to date and no individuals have dropped out of the study for reasons related to IPLEX(TM). The Company received cost recovery of $5.2 million for drug supplies for the full-year 2007.

The study utilizes a Revised ALS Functional Rating Scale (ALSFRS) to monitor the progress of the subjects. The ALSFRS is used to determine a patient's capacity and independence in several functional activities including speech, salivation, swallowing, handwriting, cutting foods and handling utensils, dressing and hygiene, turning in bed, walking, climbing stairs, and respiratory function. The purpose of collecting this information is to help ensure safety and to gain an understanding as to whether IPLEX(TM) provides any benefit to these subjects.

ALS, often referred to as Lou Gehrig's disease, is a progressive neurodegenerative disorder that affects nerve cells in the brain and spinal cord. Motor neurons reach from the brain to the spinal cord and from the spinal cord to the muscles throughout the body. The progressive degeneration of the motor neurons in ALS eventually leads to their death. When the motor neurons die, the ability of the brain to initiate and control muscle movement is lost. With voluntary muscle movement action progressively negatively affected, those patients in the later stage of the disease may become totally paralyzed. The ALS Association believes that 5,600 people in the U.S. are diagnosed with ALS annually, and an estimated 30,000 Americans suffer from the disease. Most ALS patients die within three to five years after onset of symptoms, according to the National Institute of Neurological Disorders and Stroke.

"We are pleased with the progress of the EAP for IPLEX(TM) in Italy," said Geoffrey Allan Ph.D., Insmed's President and Chief Executive Officer. "Because this disease has few treatment options, the patients participating in this study are in desperate need of effective medicines. We look forward to continuing to work with Italian health authorities and clinicians to advance this important study and, in conjunction with them, will proceed with a thorough analysis of the data from this study at an appropriate point in the future."

About IPLEX(TM)

IPLEX(TM) was approved in the United States in December 2005 for the treatment of children with growth failure due to severe primary IGF-I deficiency (Primary IGFD). IPLEX(TM) rhIGF-I/rhIGFBP-3), is a complex of recombinant human insulin-like growth factor-I (rhIGF-I) and its predominant binding protein IGFBP-3 (rhIGFBP-3). The drug is also being investigated for various other indications with unmet medical needs.

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our entrance into the follow on biologics market may be unsuccessful, our common stock could be delisted from the Nasdaq Global Market and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended September 30, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

Investor Relations Contact:

Brian Ritchie - FD

212-850-5683

brian.ritchie@fd.com

Corporate Communications Contact:

John Procter - Gibraltar Associates

202-879-5808

jprocter@gibraltar-llc.com


'/>"/>
SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy
2. EpiCept Provides Update on Clinical and Regulatory Progress with Ceplene(TM) and EpiCept(TM) NP-1 Cream
3. DuPont Provides Technology for Washington Hospital Centers Emergency Department
4. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
5. ImaRx Provides Update on TUCSON Phase I/II Clinical Trial in Acute Ischemic Stroke
6. Progen Provides Update on Phase 3 Clinical Program for PI-88 in Liver Cancer
7. IDM Pharma Provides Update of Product Pipeline and Announces Plans to Evaluate Strategic Alternatives for the Company
8. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
9. Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery
10. Replidyne Provides Strategic Update
11. BioCryst Provides Forodesine HCl Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... YORK , March 29, 2017 Global intravenous ... US$ 3 billion by 2021, growing at a CAGR of ... iron prescribed by a doctor to treat anemia or other ... iron level in the body. However, in some cases, oral ... the body and intravenous (IV) iron therapy comes into the ...
(Date:3/29/2017)... March 29, 2017  BioSpecifics Technologies Corp. (NASDAQ: ... to develop collagenase based-therapies with a first in ... as XIAFLEX ®  in the U.S. and Xiapex ... a corporate overview at the upcoming 16 th ... 5, 2017 at 8:00 a.m. ET in ...
(Date:3/29/2017)... 29, 2017 Research and Markets has announced the ... Therapy Centers & Forecast" report to their offering. ... Proton Therapy Market in Italy ... value in 2016. There are currently three proton therapy centers in ... more patients. In Italy , the first patients were ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... 2017 , ... Youth Futures International (YFI) premiered its Serve, Learn, & Empower ... college students who have participated in the program every summer. The 2017 Serve, ... applications for enrollment. Visit http://www.ghana.yfiexperience.org to learn more. , “I have ...
(Date:3/29/2017)... Rouge, Louisiana (PRWEB) , ... March 29, 2017 ... ... HeartBoost in three Hours at a Walgreens store in Mississippi. AngioGenesis Labs, makers ... at Walgreens Stores in two southeastern states. Ingredients in HeartBoost, an over the ...
(Date:3/29/2017)... Mt. Horeb, WI (PRWEB) , ... March 29, 2017 , ... ... her patients on early orthodontic treatment and accepting new pediatric patients, with or without ... can help young patients have a better orthodontic outcome and experience. When patients receive ...
(Date:3/29/2017)... ... March 29, 2017 , ... Curio Wellness , a ... the finalization of the company’s executive management team with prominent executives from both inside ... Curio Wellness’ Chief Operating Officer, Ted Dumbauld , who has more than twenty ...
(Date:3/29/2017)... Ca (PRWEB) , ... March 29, 2017 , ... Immunotherapy ... a growing number of cancers and is touted to be the next revolution in ... thus far, has been in the form of immune checkpoint inhibitors such as PD-1 ...
Breaking Medicine News(10 mins):